Black Diamond Therapeutics, Inc.BDTXNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +19.30% | +9.37% | +2.99% | +0.26% | +0.85% |
| Weighted Average Shares Diluted Growth | +19.30% | +11.32% | +2.99% | +0.75% | +0.85% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -22.66% | +23.66% | +10.93% | +14.39% | +16.61% |
| Book Value per Share Growth | -40.20% | +24.05% | +15.98% | +29.15% | +33.59% |
| Debt Growth | -12.30% | -12.05% | -12.74% | -30.28% | -32.08% |
| R&D Expense Growth | -19.57% | -21.94% | -25.27% | -42.41% | -49.34% |
| SG&A Expenses Growth | +7.40% | -25.92% | -57.17% | -32.11% | -33.66% |